Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin in movement disorders

J Jankovic1

  • 1Department of Neurology, Baylor College of Medicine, Houston, TX 77030.

Current Opinion in Neurology
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biliary Enterocytozoon bieneusi infection in a dog under immunomodulatory therapy.

The Journal of small animal practice·2023
Same author

Hyperkinetic movement disorders in congenital disorders of glycosylation.

European journal of neurology·2019
Same author

McLeod syndrome: Five new pedigrees with novel mutations.

Parkinsonism & related disorders·2019
Same author

Association between non-communicable disease multimorbidity and health care utilization in a middle-income country: population-based study.

Public health·2018
Same author

Treatment options for chorea.

Expert review of neurotherapeutics·2017
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Botulinum toxin (BTX) effectively treats muscle disorders like dystonia and spasticity. Research explores BTX mechanisms and alternative serotypes for patients developing resistance to BTX-A.

Area of Science:

  • Neurology
  • Pharmacology
  • Biochemistry

Background:

  • Botulinum toxin (BTX) is a potent neurotoxin utilized therapeutically for various conditions.
  • Its applications extend beyond movement disorders to include spasticity, bladder dysfunction, and cosmetic uses.

Purpose of the Study:

  • To review the therapeutic applications of botulinum toxin (BTX), focusing on movement disorders.
  • To discuss recent advancements in understanding the molecular and cellular mechanisms of BTX.
  • To address challenges such as immunoresistance to BTX-A and potential alternative treatments.

Main Methods:

  • Review of existing literature on botulinum toxin (BTX) therapy.
  • Analysis of clinical trial data for BTX efficacy and safety.
  • Examination of studies on BTX molecular and cellular mechanisms.

Related Experiment Videos

Main Results:

  • BTX is a highly effective therapeutic agent for neurologic, ophthalmic, and other disorders involving abnormal muscle contractions.
  • BTX-A is widely used, but approximately 5% of patients develop blocking anti-BTX-A antibodies, leading to immunoresistance.
  • Alternative BTX serotypes, such as BTX-B and BTX-F, show promise for patients resistant to BTX-A.

Conclusions:

  • Botulinum toxin (BTX) offers significant therapeutic benefits for a range of conditions, particularly movement disorders.
  • Understanding BTX mechanisms is crucial for optimizing its clinical use.
  • Development of alternative BTX serotypes is essential for managing treatment resistance.